

Observational Study of Gut Microbiota in Abemaciclib-Treated Patients With and Without Diarrhea

NCT07264998

Status	RECRUITING
Sponsor	Hubei Cancer Hospital
Enrollment	60 participants

Key Eligibility Criteria

Inclusion (4)

- Aged 18 to 75 years.
- Diagnosed with hormone receptor-positive (HR⁺) breast cancer.
- Currently receiving treatment with Abemaciclib (either as monotherapy or in combination with endocrine therapy) for a duration of at least 2 weeks.
- Willing and able to provide written informed consent for participation in the study.

Exclusion (4)

- History of major gastrointestinal diseases, such as inflammatory bowel disease, Crohn's disease, ulcerative colitis, or intestinal obstruction, or having undergone major gastrointestinal surgery.
- Recent use (within 1 month) of antibiotics, probiotics, or traditional Chinese medicine that may alter gut function.
- Pregnant or lactating women.
- Unwilling to provide informed consent or considered by the investigator to be unsuitable for the study for any other reason.

Locations (1 total)

Hubei Cancer Hospital, Wuhan, Hubei, China